A subsequent systematic review and meta-analysis confirmed a lower incidence of obesity-associated cancers and reduced all-cause mortality among patients with diabetes and obesity treated with GLP-1RAs compared to those using DPP-4 inhibitors [80]. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.